Analysts have been eager to weigh in on the Healthcare sector with new ratings on Premier (PINC – Research Report), Tarsus Pharmaceuticals (TARS – Research Report) and Novavax (NVAX – Research Report).
Premier (PINC)
In a report released yesterday, Michael Cherny from Bank of America Securities maintained a Sell rating on Premier, with a price target of $31.00. The company’s shares closed last Thursday at $27.57.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Premier with a $32.67 average price target.
See the top stocks recommended by analysts >>
Tarsus Pharmaceuticals (TARS)
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Tarsus Pharmaceuticals yesterday and set a price target of $42.00. The company’s shares closed last Thursday at $18.62.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tarsus Pharmaceuticals with a $47.25 average price target.
Novavax (NVAX)
Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Novavax yesterday and set a price target of $9.00. The company’s shares closed last Thursday at $8.06, close to its 52-week low of $5.61.
According to TipRanks.com, Stranahan is a 3-star analyst with an average return of
Currently, the analyst consensus on Novavax is a Hold with an average price target of $17.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PINC:
